clinical trials

Bayer’s blockbuster pipeline promises broken by a PhII setback for top cancer drug
Bayer’s blockbuster pipeline promises broken by a PhII setback for top cancer drug
Endpoints
Bayer
clinical trials
anetumab ravtansine
mesothelioma
Flag link:
Mylan, Theravance’s inhaled COPD therapy proves safe in late-stage trial
Mylan, Theravance’s inhaled COPD therapy proves safe in late-stage trial
Drug Delivery Business News
Mylan
Theravance
COPD
clinical trials
revefenacin
Flag link:
FDA Collaborates to Promote Safety, Quality in Clinical Trials Done in India
FDA Collaborates to Promote Safety, Quality in Clinical Trials Done in India
Mass Device
FDA
India
clinical trials
Flag link:
Paratek goes 3-for-3 in PhIII, but antibiotic stumbles on side effect profile
Paratek goes 3-for-3 in PhIII, but antibiotic stumbles on side effect profile
Endpoints
Paratek
antibiotics
clinical trials
side effects
omadacycline
Flag link:
FDA Collaborates to Promote Safety, Quality in Clinical Trials Done in India
FDA Collaborates to Promote Safety, Quality in Clinical Trials Done in India
FDA Voice
FDA
India
clinical trials
Flag link:
Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx
Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx
Yahoo/Zacks.com
Exelixis
Bristol-Myers Squibb
clinical trials
Opdivo
Opdivo-Cabometyx
renal cell carcinoma
Flag link:
Arena takes a big step down the comeback trail with PhII success, shares rocket up
Arena takes a big step down the comeback trail with PhII success, shares rocket up
Endpoints
Arena Pharmaceuticals
PAH
clinical trials
pulmonary arterial hypertension
ralinepag
Flag link:
How Reproducible are Preclinical Study Results?
How Reproducible are Preclinical Study Results?
Xtalks
preclinical study results
cancer
oncology
clinical trials
Flag link:
After a quick trial revamp, FDA lifts its clinical hold on Concert’s hair-loss drug
After a quick trial revamp, FDA lifts its clinical hold on Concert’s hair-loss drug
Endpoints
FDA
clinical trials
Concert Pharmaceuticals
CTP-543
alopecia areata
hair loss
Flag link:
What the FDA's Hold on Three Merck Studies Means for Other Drug Makers
What the FDA's Hold on Three Merck Studies Means for Other Drug Makers
TheStreet.com
Merck
Keytruda
FDA
clinical trials
Multiple Myeloma
Bristol-Myers Squibb
AstraZeneca
Celgene
Flag link:
Sanofi and Alnylam plunge into PhIII with a rival to Roche’s top hemophilia drug
Sanofi and Alnylam plunge into PhIII with a rival to Roche’s top hemophilia drug
Endpoints
Sanofi
Alnylam
clinical trials
fitusiran
hemophilia
Roche
emicizumab
Flag link:
Sorrento Therapeutics Gets FDA Go-Ahead for Cancer Pain Clinical Trial
Sorrento Therapeutics Gets FDA Go-Ahead for Cancer Pain Clinical Trial
Xtalks
Sorrento Therapeutics
clinical trials
FDA
cancer pain
Resiniferatoxin
Flag link:
Troubled by deaths, FDA orders Merck to slam the brakes on three Keytruda studies
Troubled by deaths, FDA orders Merck to slam the brakes on three Keytruda studies
Endpoints
FDA
Merck
Keytruda
clinical trials
Multiple Myeloma
Flag link:
Novo Nordisk touts late-stage trial data for Tresiba insulin injection
Novo Nordisk touts late-stage trial data for Tresiba insulin injection
Drug Delivery Business News
Novo Nordisk
Tresiba
insulin
clinical trials
diabetes
Flag link:
The Importance of the Safety Management Plan for Clinical Trials
The Importance of the Safety Management Plan for Clinical Trials
Elsevier
clinical trials
drug safety
Flag link:
Cara tries hard to spin the data, but key PhIIb pain study fails and shares slide south
Cara tries hard to spin the data, but key PhIIb pain study fails and shares slide south
Endpoints
Cara Therapeutics
clinical trials
CR845
osteoarthritis
Flag link:
Side Effect Weighs on Early Results for Alkermes’ Schizophrenia Drug
Side Effect Weighs on Early Results for Alkermes’ Schizophrenia Drug
Xconomy
Alkermes
schizophrenia
side effects
ALKS 3831
clinical trials
Flag link:
Alkermes claims a success in PhIII schizophrenia head-to-head, but where’s the benefit for patients?
Alkermes claims a success in PhIII schizophrenia head-to-head, but where’s the benefit for patients?
Endpoints
Alkermes
schizophrenia
ALKS 3831
clinical trials
Flag link:
Investors — and AstraZeneca CEO Pascal Soriot — are getting a tad nervous as MYSTIC data loom
Investors — and AstraZeneca CEO Pascal Soriot — are getting a tad nervous as MYSTIC data loom
Endpoints
investors
AstraZeneca
Pascal Soriot
Imfinzi
tremelimumab
immuno-oncology
clinical trials
Flag link:
Eyeing a $6B market, Bavarian Nordic posts positive phase 2 data for universal RSV vaccine
Eyeing a $6B market, Bavarian Nordic posts positive phase 2 data for universal RSV vaccine
Fierce Pharma
Bavarian Nordic
clinical trials
vaccines
RSV
Flag link: